Replies to post #41410 on OncoSec Medical Inc (ONCSQ)

[hschlauch]

I also concur with the value of licensing, and after seeing the abstract for the first reported multigene construct, I am inclined to think that the platform could be used for personalized cancer vaccines. This approach could be licensed for many solid tumor types and at various stages of disease progression. Systemic anti-PD-1 will still need to be coupled with the intratumoral therapy, therefore companies with approved checkpoint inhibitors would benefit greatly. And Merck may just be the tip of the iceberg.

[bradrad]

With all studies being completed with Keytruda, would ONCS have to start over with trials for other indications?

I agree licensing could be lucrative but what’s the timeline for usage with other indications?